EUVIMEDEUVIMED entdecken
Crossref

Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis

Nasser Mikhail

Clinical Cardiology and Cardiovascular Interventions · 07.05.2026 · 09 (07) · 01-06

DOI: 10.31579/2641-0419/573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Cardiology and Cardiovascular Interventions, online erschienen am 07.05.2026. Verfasst von Nasser Mikhail.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apolipoprotein C3 (ApoC3) is a glycoprotein that normally increases levels of plasma triglycerides. Thus, Apo C3 inhibitors such as olezarsen and plozasiran result in reduction of triglycerides levels. In 2 phase 3 clinical trials of patients having familial chylomicronemia syndrome (FCS), olezarsen 80 mg administered subcutaneously every 4 weeks decreased triglycerides by -43.5 % (95% CI, -69.1 to -17.9; P

Zitieren

APA

Mikhail, N. (2026). Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis. Clinical Cardiology and Cardiovascular Interventions, 09(07), 01-06. https://doi.org/10.31579/2641-0419/573

Vancouver

Mikhail N. Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis. Clinical Cardiology and Cardiovascular Interventions. 2026;09(07):01-06. doi:10.31579/2641-0419/573

BibTeX
@article{Mikhail2026,
  author = {Mikhail, Nasser},
  title = {Olezarsen and Plozasiran: the First Effective Pharmacological Therapy to Prevent Hypertriglyceridemia-induced Acute Pancreatitis},
  journal = {Clinical Cardiology and Cardiovascular Interventions},
  year = {2026},
  volume = {09},
  number = {07},
  pages = {01--06},
  doi = {10.31579/2641-0419/573}
}
Kostenlos starten →